SPECT

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on: 
Lunedì, Aprile 29, 2024
Technology, Insurance, Health Technology, Professional Services, Cardiology, Health Insurance, Software, General Health, Health, Artificial Intelligence, Use, Radiation, University, Part, Telehealth, Diagnosis, AUC, Hospital, SPECT, Care, Cardiovascular disease, Prevalence, Molina Healthcare, Methylation, American Medical Association, Death, DNA methylation, MD, Doctor of Philosophy, CHD, Advances in Therapy, DNA, Algorithm, Patient, Moyamoya disease, CPT, PLA, Medicare, Biomarker, Intermountain Health, Associate, Medicine, VBC, Economics, CCTA, Journal, American Heart Association

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points: 
  • PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
  • The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
  • The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
  • These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Martedì, Aprile 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

Retrieved on: 
Lunedì, Aprile 8, 2024
Party, Partnership, Patient, PET, Acquisition, Radiopharmaceutical, MENA, SPECT, Nuclear medicine, Medical imaging

PARIS, April 08, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an agreement with Eczacıbaşı Holding and Bozlu Group for the acquisition of Eczacıbaşı-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET & SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.

Key Points: 
  • It will expand Curium’s PET footprint of 34 sites in Western Europe and Asia with the addition of 12 owned and partnered sites in Eastern Europe and MENA regions.
  • In addition, Eczacıbaşı-Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, will add significant scale to Curium’s vertically integrated production and distribution capabilities.
  • Eczacıbaşı Holding and Curium are fully committed to navigating through this process efficiently and expect to finalize the transaction in due course.
  • The Parties expect to be able to close this transaction once the customary regulatory approvals will have been obtained.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Giovedì, Marzo 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Lunedì, Aprile 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Retrieved on: 
Giovedì, Marzo 28, 2024
FDA, Health, Technology, Clinical Trials, Artificial Intelligence, Cardiology, Diagnosis, Coronary ischemia, Patient, Myocardial perfusion imaging, Journal, Ischemia, MD, American College, CCTA, Stenosis, Atherosclerosis, SPECT, Medical device

The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.

Key Points: 
  • The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.
  • For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up.
  • Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.
  • These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580.

Spectrum Dynamics is proud to announce the Installation of the VERITON-CT SPECT/CT imaging system at European Leading Cancer Center, Gustave Roussy

Retrieved on: 
Giovedì, Marzo 21, 2024
Toxicity, CZT, Algorithm, Patient, Neoplasm, Hospital, 3D, Cancer, Gustave Roussy, Google Images, The, SPECT, SPECT/CT, Newsweek, Nuclear medicine, Health, Medical imaging

Gustave Roussy is considered as a leading cancer centre in Europe.

Key Points: 
  • Gustave Roussy is considered as a leading cancer centre in Europe.
  • The institute treats patients with all types of cancer at any age and is a leading institution in the treatment of rare and complex tumors.
  • It is unlike any other ring-shaped gantry, with a 360o CZT 12-detector design that automatically moves close to the patient's body.
  • "We are delighted to collaborate with Gustav Roussy with the install of the VERITON-CT 400 SPECT/CT scanner," says Johann Fernando, Executive Vice President, Spectrum Dynamics.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Retrieved on: 
Martedì, Marzo 5, 2024
Neoplasm, Actinium-225, SPECT, MD, Radionuclide, Therapy, Receptor (biochemistry), Patient, Radiopharmaceutical, Pancreatic cancer, Cancer, Medical imaging

This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.

Key Points: 
  • This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.
  • Two of the most commercially successful radiopharmaceuticals, Pluvicto® and Lutathera™, use the therapeutic radioisotope Lutetium-177 (Lu-177).
  • Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model.
  • “These data further support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients with uPAR-positive tumors.”

Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic

Retrieved on: 
Giovedì, Febbraio 22, 2024
Radiopharmaceutical, European Commission, SPECT, Physician, Marketing, FDA, Food, Cancer, PSMA, Agency, INN, Death, Civil service commission, European Medicines Agency, AG, Patient, Nuclear medicine, Prostate cancer, Diagnosis, PCA, PET, Medical imaging

Dr. Michel Wuillemin, Head of Radiopharmaceuticals at b.e.imaging, commented, “b.e.Imaging is proud of the submission of the marketing authorization application for PYLCLARI® to Swissmedic ahead of schedule.

Key Points: 
  • Dr. Michel Wuillemin, Head of Radiopharmaceuticals at b.e.imaging, commented, “b.e.Imaging is proud of the submission of the marketing authorization application for PYLCLARI® to Swissmedic ahead of schedule.
  • We are fully dedicated to improving the situation of prostate cancer patients in Switzerland.”
    Benoit Woessmer, PET Europe CEO at Curium, commented, “The acceptance of the marketing authorization application by Swissmedic for PYLCLARI® is another important milestone for prostate cancer patients in Switzerland.
  • We look forward to providing an improved choice of tools available to physicians for the diagnosis of prostate cancer patients.
  • Marketing authorization for PYLCLARI® (also known as (18F)-DCFPyL) was granted in July 2023 by the European Commission.

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Retrieved on: 
Martedì, Marzo 5, 2024
Diagnosis, Isotope, Therapy, PET, Research, SPECT, Pharmaceutical industry

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.

Key Points: 
  • With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.
  • Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates.
  • Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space.
  • We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition."